在关节卸载过程中,甲诱导的自主肌肉活动下降伴随着保存的缓慢肌mRNA表达
Kristina A Sharlo1, Irina D Lvova1, Sergey A Tyganov1
1Myology Laboratory, Institute of Biomedical Problems, Russian Academy of Sciences, 123007 Moscow, Russia.
Current issues in molecular biology
|July 28, 2023
概括
普罗克佩拉可以防止肌肉纤维的变化和因不使用而导致的功能下降. 在老鼠中,这种药物可能会阻止缓慢的肌肉纤维转化为快速,疲劳的纤维.
科学领域:
- 肌肉生理学和细胞生物学
- 骨肌肉适应的药理学
- 生物医学研究的废弃使用缩.
背景情况:
- 骨肌的不使用会导致病态活动和从缓慢纤维类型转变为快速纤维类型.
- 快速类型的纤维更容易疲劳,导致肌肉功能减弱.
- 之前的研究表明,甲基可降低未负荷的老鼠肌肉的电活动.
研究的目的:
- 为了研究前烯对废弃的骨肌肉中纤维类型转换的作用.
- 为了确定是否能防止与肌肉不使用相关的功能衰退.
- 探索潜在的机制,包括和活性氧物种 (ROS) 信号传输,涉及到前甲的作用.
主要方法:
- 给大鼠注射甲甲的注射.
- 在大鼠模型中诱导骨肌肉不使用.
- 对骨肌肉纤维类型组成的分析.
- 研究和ROS相关的信号通路.
主要成果:
- 普罗克佩拉的使用阻断了老鼠骨肌肉中缓慢变快的纤维类型转化.
- 药物的作用可能与和ROS信号的调节有关.
- 这些发现表明,普罗克洛普拉在缓解使用不良引起的肌肉功能障碍方面具有潜在的治疗作用.
结论:
- 普罗克佩拉有效地防止了废弃的骨肌肉中有害的纤维类型变化.
- 该机制可能涉及细胞内和活性氧物种的调节.
- 这项研究突出显示了普洛克佩拉作为一种潜在的治疗药物,用于涉及骨肌肉不使用的疾病.
相关概念视频
Classification of Skeletal Muscle Relaxants
2.5K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.5K
Skeletal Muscle Relaxants: Adverse Effects
401
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
401
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
458
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
458
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.4K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.4K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
311
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
311
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.9K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.9K


